Lexicon Pharmaceuticals Inc

In a Stage 2 advancing market within a long-term uptrend, medium-term bias remains bullish supported by persistent higher highs/lows and rising moving averages; short-term timing is favorable as price pulls back and holds the rising 9 and 21 EMAs, warranting a Buy Now stance at the EMA support zone.

• ↑Full-year 2025 revenue $49.8M, up 720% since 2022
• ↑Licensing revenue of $17.5M from Novo Nordisk due H2 2026
• ↓2025 net loss of $50.3M highlights persistent profitability issues